Santen Pharmaceutical Co., Ltd. provided consolidated earnings forecasts for the fiscal year ending March 31, 2025. For the year, on a core basis, the company expects revenue of ¥297,000 million, core operating profit of ¥55,000 million, core net profit for the year of ¥41,250 million and basic core earnings per share of ¥117.05. On IFRS basis, the company expects revenue of ¥297,000 million, operating profit of ¥44,500 million, net profit for the year of ¥33,500 million and basic earnings per share of ¥92.22.